Tag: oligonucleotide therapeutics

DNA Replication Demand: Driving Contract Manufacturing Market

Since the approval of the first antisense therapy in 1998, DNA replication has been in light for their capabilities as therapeutic agents. DNA replication provides a short synthetic nucleotide chain with immense potential in the diagnosis and treatment of a myriad of disease indications. In addition to therapeutics, these complex molecules act as a significant

Oligonucleotide Therapeutics: A Driving Force for CMOs

In the 20th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as Oligonucleotide therapeutics. These short, single-stranded DNA or RNA molecules, which are the product of DNA manufacturing services, have various applications in biopharmaceutical and biotechnology